Avista Pharma Solutions, Inc.

Targacept, Inc.

Catalyst Biosciences, Inc.

Other

Advitech Advisory and Technologies Sa

Attenua, Inc.

Jason Daniel Speake

Joe B Perales

Daniel Yohannes

Weiming Fan

Balwinder Singh Bhatti

Srinivasa Rao Akireddy

Brent Christopher Beck

Yunde Xiao

Matt S Melvin

Ronald Joseph Heemstra

Bharathi Pandi

Solene Clarisse Rolland

Merouane Bencherif

Anatoly A Mazurov

Julio A Munoz

Kristen G Jordan

Terry Hauser

Sharon Rae Letchworth

Joseph Alexander Moore, Iii

Keqiang Li

Nikolai Fedorov

Jeffrey A Adams

Cyprian Okwara Ogbu

Brian H Heasley

Jennifer Freeman

Hao Liu

Ilaria Ferrando

Nikolai Federov

Cisco Bee

Jessica Marie Sligar

Solène Clarisse Rolland

Bakela Nare

Kurt S Van Horn

Kristen Jordan

The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.

Synthetic process and intermediates

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.

Chemical compounds

The present invention relates to a process for the preparation of rucaparib; the invention also refers to novel intermediates of synthesis as well as their use in the preparation of i.a. rucaparib.

Process for the preparation of rucaparib and novel synthesis intermediates

The present invention relates to single enantiomer isothiazoline compounds of formula (I): and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.

Single enantiomer antiparasitic compounds

The present invention relates to isothiazoline compounds of formula (I). The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to veterinary compositions comprising said compounds.

Antiparasitic compounds

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.

Sulfonamide derivatives as JAK inhibitors

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for use, and their pharmaceutical compositions.

Nicotinic receptor non-competitive antagonists

The present invention describes compounds of Formula (I): or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of Formula (I) have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of Formula (I), which are EP4 receptor antagonists.

Substituted ureas as prostaglandin EP4 receptor antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

The present invention describes novel compounds, or veterinary or pharmaceutically acceptable salts thereof, veterinary or pharmaceutical compositions thereof, and medical uses thereof. The compounds of the invention have activity as prostaglandin EP4 receptor antagonists and are useful in the treatment or alleviation of pain, inflammation and inflammation-associated disorders. Also described herein are methods for treating pain by administering the compounds of the invention. For example, the invention describes 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-a]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyflurea of the formula: veterinary or pharmaceutical compositions thereof, and methods of treatment using the subject compound and compositions thereof.

Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-&#x3b1;]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist

Growing community of inventors

Winston-Salem, NC, United States of America

Jason Daniel Speake